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Middle East respiratory syndrome coronavirus (MERS-CoV) is continuously spreading and causing severe
and fatal acute respiratory disease in humans. Prophylactic and therapeutic strategies are therefore ur-
gently needed to control MERS-CoV infection. Here, we generated a humanized monoclonal antibody
(mAb), designated hMS-1, which targeted the MERS-CoV receptor-binding domain (RBD) with high af-
ﬁnity. hMS-1 signiﬁcantly blocked MERS-CoV RBD binding to its viral receptor, human dipeptidyl
peptidase 4 (hDPP4), potently neutralized infection by a prototype MERS-CoV, and effectively cross-
neutralized evolved MERS-CoV isolates through recognizing highly conserved RBD epitopes. Notably,
single-dose treatment with hMS-1 completely protected hDPP4 transgenic (hDPP4-Tg) mice from lethal
infection with MERS-CoV. Taken together, our data suggest that hMS-1 might be developed as an
effective immunotherapeutic agent to treat patients infected with MERS-CoV, particularly in emergent
cases.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV), ﬁrst
isolated from a Saudi Arabian patient in September 2012 (Zaki et al.,
2012), causes human infection in other parts of the world and thus
has become a global concern. In particular, an outbreak in South
Korea in 2015 resulted in 186 infections with 36 deaths (http://aximal effective concentra-
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B.V. This is an open access article uwww.who.int/csr/don/21-july-2015-mers-korea/en/). As of March
16, 2016, a total of 1,690 laboratory-conﬁrmed cases including over
600 deaths have been reported (http://www.who.int/emergencies/
mers-cov/en/), representing a mortality rate of 36%. The symptoms
caused by MERS-CoV are similar to those from severe acute respi-
ratory syndrome coronavirus (SARS-CoV), a related coronavirus
with a 10% fatality rate that led to the 2002e2003 epidemic
(Skowronski et al., 2004; Zhong et al., 2003). Unlike SARS-CoV, for
which no additional cases have been reported since 2005 (Du et al.,
2009), MERS-CoV has shown continually increasing numbers of
cases, particularly in Saudi Arabia, suggesting its potential future
epidemic status. Nevertheless, no clinically approved vaccines or
antiviral therapeutics are currently available, highlighting the ur-
gent need of potent strategies to combat this virus.
MERS-CoV belongs to the Betacoronavirus genus of the corona-
virus family (de Groot et al., 2013; Zaki et al., 2012). Its spike pro-
tein, consisting of S1 and S2 subunits, plays important roles in viral
entry into host cells (Bonavia et al., 2003; Gao et al., 2013; Xu et al.,
2004). MERS-CoV depends on the receptor-binding domain (RBD)
in the S1 subunit to bind to its viral receptor, human dipeptidylnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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S2 subunit undergoes a dramatic conformational change to allow
for membrane fusion and subsequent MERS-CoV penetration into
the cellular membrane (Gao et al., 2013; Lu et al., 2013; Raj et al.,
2013; Wang et al., 2013). Therefore, the entry of MERS-CoV into
target cells might be prevented by either blocking RBD/DPP4 viral
receptor binding or by inhibiting MERS-CoV/host cell membrane
fusion.
Vaccines and passive therapeutics are effective approaches
against viral infections. In general, vaccines cannot provide im-
mediate prophylactic protection against or treatment of ongoing
viral infection. In comparison, passive therapeutics based on
neutralizing monoclonal antibodies (mAbs) has emerged as a
powerful tool to provide prophylactic and therapeutic protection
against viral infection (Du et al., 2013a; Zhu et al., 2013). Several
human or humanized viral-neutralizing mAbs have been devel-
oped, almost all of which target the RBD (Corti et al., 2015; Jiang
et al., 2014; Li et al., 2015; Pascal et al., 2015; Tang et al., 2014;
Ying et al., 2014; Yu et al., 2015), further suggesting that MERS-
CoV RBD represents an ideal target for neutralizing mAb
development.
We previously developed amurinemAb, Mersmab1, that targets
MERS-CoV RBD and potently neutralizes MERS-CoV infection (Du
et al., 2014). Here, we humanized Mersmab1 and generated a hu-
manized mAb, hMS-1, which exhibited high afﬁnity RBD binding.
We ﬁrst investigated the activity as well as the mechanism of hMS-
1 in neutralizing MERS-CoV cell entry. Second, we evaluated its
ability to neutralize emergent MERS-CoV strains. Finally, we
demonstrated that single-dose treatment with hMS-1 was able to
elicit full protection against lethal MERS-CoV infection in an hDPP4
transgenic (hDPP4-Tg) mousemodel. Of note, hMS-1 represents the
ﬁrst mAb reported to exhibit this capacity to protect treated ani-
mals from the lethal infection of MERS-CoV.
2. Materials and methods
2.1. Ethics statement
Animal studies were performed in strict accordance with the
recommendations of the Guide for the Care and Use of Laboratory
Animals. The animal protocol was approved by the IACUC of the
Laboratory Animal Center, State Key Laboratory of Pathogen and
Biosecurity, Beijing Institute of Microbiology and Epidemiology
(Permit number, BIME 2015-0023). All procedures involving MERS-
CoV were carried out in an approved biosafety level 3 facility.
2.2. Preparation of recombinant proteins
MERS-CoV RBD proteins were prepared as previously described
(Ma et al., 2014). Brieﬂy, MERS-CoV RBDs (GenBank accession no.
AFS88936.1, residues 377e588 of the spike protein) fused with a C-
terminal human Fc or His6 tag were transiently expressed in a 293T
cell culture system and puriﬁed using HiTrap Protein A FF (Fc-fused
proteins) or HisTrap HP (His6-tagged proteins) (GE Healthcare,
Little Chalfont, UK). Mutant RBD proteins were generated by site-
speciﬁc polymerase chain reaction (PCR) mutagenesis and
conﬁrmed by sequencing analysis. Mutant RBDs containing a C-
terminal His6 tag were transiently expressed in 293T cell super-
natants and puriﬁed by HisTrap HP as described above.
2.3. Generation of humanized mAb hMS-1
The hMS-1 mAbwas generated by humanizing the murine mAb
Mersmab1 using a previously described protocol (Boulianne et al.,
1984). Brieﬂy, total RNA was isolated from the Mersmab1hybridoma cells and used to synthesize cDNA. Primers mVH-f (50
ATG GRA TGGAGC TGG ATC TT 30) andmVH-r (50 ATAGAC AGA TGG
GGG TGT CGT TTT GGC 30) were used to amplify the variable region
of the heavy chain (VH) gene, andmVK-f (50 ATG GAGWCAGAC ACA
CTC CT 30) and mVK-r (50 GGA TACA GTT GGT GCA GCA TC 30) (Du
et al., 2013a) were used for the variable region of the light chain
(VL) gene. Sequence-conﬁrmed VH and VL genes were inserted into
the pRBO/Ig expression vector (containing human IgG1-and human
immunoglobulin kappa chain constant regions). Recombinant
plasmid was transfected into 293F cells and humanized mAb was
puriﬁed from the cell culture supernatants. Puriﬁed hMS-1 mAbs
were resolved by reducing 12% sodium dodecyl sulphate-
polyacrylamide electrophoresis (SDS-PAGE) and non-reducing 8%
SDS-PAGE, respectively.
2.4. Enzyme-linked immunosorbent assay (ELISA)
The reactivity of hMS-1 and MERS-CoV RBD was detected by
ELISA as described (Du et al., 2014). Brieﬂy, ELISA plates were
coated overnight at 4 C with His6-tagged RBD protein (1 mg/ml)
and blocked with 2% no-fat milk at 37 C for 2 h. Serial diluted hMS-
1 or trastuzumab control (Roche, Roswell, GA, USA) was added to
the plates and incubated at 37 C for 1 h. Horseradish peroxidase-
conjugated goat anti-human IgG (1:5,000, Santa Cruz Biotech-
nology, Dallas, TX, USA) was then added and further incubated at
37 C for 1 h. The reactionwas visualized by TMB substrate addition
(Invitrogen, Carlsbad, CA, USA) and stopped by 1N H2SO4. The
absorbance at 450 nm was measured using an ELISA plate reader
(BioTek, Winooski, VT, USA). The half-maximal effective concen-
tration (EC50) of hMS-1 was calculated using GraphPad Prism 5.01
software (La Jolla, CA, USA). hMS-1 epitope mapping was per-
formed by ELISA as described above except that the ELISA plates
were coated with a series of mutant RBD proteins (2.5 mg/ml).
2.5. Surface plasmon resonance (SPR)
The afﬁnity of hMS-1 binding to theMERS-CoV RBDwas assayed
using a Biacore T100 instrument (GE Healthcare, Little Chalfont,
UK). hMS-1 (5 mg/ml) was immobilized on a CM5 sensor chip with
an amine coupling kit. The reference ﬂow cell was treated with
amine coupling reagent without exposure to hMS-1. The running
buffer was HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM
EDTA, and 0.05% surfactant P20). His6-tagged RBD protein at
gradient concentrations (2, 4, 8, 16, and 32 nM)was ﬂowed over the
chip surface. The chip was regenerated with 100 mM H3PO4. The
sensorgram was analyzed using BIAevaluation software, and the
data were ﬁtted to a 1:1 binding model.
2.6. MERS-CoV neutralization assay
TheMERS-CoV neutralization assay was performed as described
(Du et al., 2013b; Tao et al., 2013). Brieﬂy, serially 2-fold-diluted
hMS-1 or a trastuzumab control was incubated with 100 50% tissue
culture infective doses (TCID50) of MERS-CoV at 37 C for 1 h fol-
lowed by incubationwith Vero cells at 37 C for 72 h. The cytopathic
effect (CPE) was observed daily and recorded on day 3 following
inoculation. The 50% neutralizing dose (ND50) was calculated by the
Reed-Muenchmethod (Reed andMuench,1938) and determined as
the antibody concentration that completely inhibited virus-
induced CPE in at least 50% of the wells.
2.7. Flow cytometric analysis
Determination of the hMS-1 inhibitory ability against the
binding between MERS-CoV RBD and hDPP4-expressing Huh-
Fig. 1. Analysis of hMS-1 expression. The expression of hMS-1 was resolved by
reducing 12% SDS-PAGE (A) and non-reducing 8% SDS-PAGE (B) respectively, followed
by Coomassie blue staining. Prestained protein molecular-weight markers (kDa)
(Thermo Scientiﬁc) are indicated on the left of each panel.
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2013b). Brieﬂy, Huh-7 cells (5  105) were incubated with Fc-
fused RBD protein (2 mg/ml) in the presence of serially diluted
hMS-1 or with the trastuzumab control at room temperature for
30 min, followed by incubationwith DyLight 488-labeled goat anti-
human IgG antibody at room temperature for 30 min. The ﬂuo-
rescence signals were analyzed by ﬂow cytometry (Guava, EMD
Millipore, Germany).
2.8. Pseudovirus neutralization assay
The pseudovirus neutralization assay was performed as
described (Zhao et al., 2013). Brieﬂy, 293T cells were co-transfected
with plasmids encoding an Env-defective, luciferase-expressing
HIV-1 genome (pNL4-3.luc.RE) and encoding the MERS-CoV spike
protein (EMC2012 strain) or MERS-CoV emergent strains with the
corresponding RBD mutations, to package pseudotyped MERS-
CoVs. Pseudoviruses were incubated with serially diluted hMS-1
at 37 C for 1 h and the mixture was then added to Huh-7 cells
pre-plated in 96-well tissue culture plates (104/well) 6 h before
inoculation. After 72 h, the cells were lysed with cell lysis buffer
(Promega, Madison, WI, USA) and transferred into 96-well lumin-
ometer plates. The luciferase activity was determined using an
Inﬁnite M1000 luminometer (Tecan, San Jose, CA, USA). ND50 was
calculated using the dose-response inhibition model in GraphPad
Prism.
2.9. Multiple sequence alignment of MERS-CoV RBDs
A total of 278 full-length spike protein sequences were collected
from the MERS Coronavirus Database of The Virus Variation
Resource (Brister et al., 2014) for multiple sequence alignment
using the MUSCLE program (Edgar, 2004). GenBank accession
numbers of selectedMERS-CoV isolates are listed in Supplementary
materials and methods.
2.10. Animal infection and antiviral therapy
We used 8e10-week-old female hDPP4-Tg mice to evaluate the
hMS-1 passive therapeutic effect against lethal MERS-CoV infection
(Zhao et al., 2015). Following intraperitoneal anesthetization with
sodium pentobarbital (5 mg/kg of body weight), mice under lethal
virus infection were intranasally inoculated with 104.6 TCID50
MERS-CoV (EMC2012 strain) in 20 ml Dulbecco’s modiﬁed Eagle’s
medium (DMEM). After 24 h, the mice were intravenously injected
with 2 mg/kg puriﬁed hMS-1 or the trastuzumab mAb control.
Infected mice were observed for 23 days to calculate the body
weight change and survival rate. Additionally, 5 mice were sacri-
ﬁced from each group on day 3 post-infection and lung tissues were
collected for virological detection and histopathological evaluation.
2.11. Viral titer detection
Viral titer was detected as described (Zhao et al., 2015). Brieﬂy,
mouse lung tissues were homogenized in DMEM plus antibiotics to
achieve 10% (w/v) suspensions, which were then titrated on
monolayers of Vero cells in quadruplicate. The CPE was observed
daily under phase-contrast microscopy for 3 days. The viral titer
was calculated by the Reed-Muench method and expressed as
log10TCID50/g of tissue.
2.12. Histopathology analysis
Collected tissues were immediately ﬁxed in 10% neutral buffered
formalin and then embedded in parafﬁn. Sections (4 mm inthickness) were generated, mounted onto slides, and stained by
hematoxylin and eosin (H&E). Histopathological changes were
observed using light microscopy. The extent of lung injury was
scored according to the levels of degeneration and necrosis of the
bronchi and bronchiolar epithelium, inﬁltration of inﬂammatory
cells, alveoli degeneration and collapse, expansion of the paren-
chymal wall, hemorrhage, and interstitial edema (Sun et al., 2013).
2.13. Statistics
Statistical analyses were performed using GraphPad Prism
version 5.01. The signiﬁcance between survival curves was
analyzed by Kaplan-Meier survival analysis with a log-rank test.
Other data were analyzed using the 2-tailed unpaired t-test with
Welch’s correction. p < 0.05 was considered signiﬁcant.
3. Results
3.1. Humanized mAb hMS-1 binds to MERS-CoV RBD with high
afﬁnity
Humanized mAb hMS-1 was expressed in 293F cells and puri-
ﬁed by HiTrap Protein A FF. Reducing and non-reducing SDS-PAGE
showed that hMS-1 migrated as a single protein of approximately
180 kDa and dissociated into heavy and light chains of about 50 and
26 kDa under reducing conditions (Fig. 1A and B), in accordance
with the characteristics of a humanized antibody. The reactivity of
hMS-1 to MERS-CoV RBD was subsequently measured by ELISA. As
shown in Table 1, hMS-1 maintained the ability of the parental
Meramb1 mAb to react strongly with MERS-CoV RBD, with an EC50
of 1.67 mg/ml. Comparatively, the trastuzumab control did not react
with RBD (data not shown). The interaction between hMS-1 and
MERS-CoV RBDwas also characterized by SPR, showing a Kd of 44.7
pM. These results suggest that a humanized mAb, hMS-1, was
successfully generated, which exhibited high afﬁnity MERS-CoV
RBD binding.
3.2. Humanized mAb hMS-1 neutralizes MERS-CoV infection by
blocking the binding of MERS-CoV RBD to the hDPP4 receptor
The neutralizing activity of hMS-1 against live MERS-CoV
infection was determined. hMS-1 could potently neutralize infec-
tion of live MERS-CoV (EMC2012 strain) in permissive Vero cells
with an ND50 of 3.34 mg/ml (Table 1) whereas trastuzumab did not
exhibit antiviral activity against MERS-CoV infection. These results
suggest that humanized hMS-1 maintained the potent ability to
neutralize MERS-CoV infection.
Table 1
Characteristics of humanized hMS-1 mAb.
Binding kineticsa EC50 (mg/ml)b ND50 (mg/ml)c
kon (M1$s1) koff (s1) KD (M)
hMS-1 1.82  106 8.17  105 4.47  1011 1.67 3.34
a The binding kinetics of hMS-1 to MERS-CoV RBD was measured by BIAcore.
b The RBD-speciﬁc reactivity (EC50) of hMS-1 was determined by ELISA.
c The neutralizing activity (ND50) of hMS-1 was determined using a live MERS-CoV-based neutralization assay.
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mechanism was thus investigated by measuring its ability to block
the binding between MERS-CoV RBD and the hDPP4 receptor by
ﬂow cytometric analysis (Du et al., 2014). Whereas high ﬂuores-
cence intensity was detected in Huh-7 cells incubated with RBD
protein alone, only background ﬂuorescence levels were observed
in the RBD-Huh-7 binding samples in the presence of hMS-1 at
5 mg/ml. This suggested that hMS-1 was able to strongly block the
binding between MERS-CoV RBD and cell-associated hDPP4
(Fig. 2A) and that the blocking effect occurred in a dose-dependent
manner (Fig. 2B). In contrast, trastuzumab did not affect MERS-CoV
RBD binding to the DPP4-expressing Huh-7 cells (Fig. 2A and B).
These results strongly suggest that hMS-1 neutralized MERS-CoV
infection by inhibiting the binding of MERS-CoV RBD to hDPP4.3.3. Humanized mAb hMS-1 recognizes conserved RBD epitopes
and cross-neutralizes MERS-CoV evolutionary strains
To identify the epitopes on the MERS-CoV RBD recognized by
hMS-1, we utilized a panel of mutant RBD proteins generated by
mutating the key residues at the MERS-CoV RBD and the hDPP4
binding interface to alanine (Du et al., 2014); the binding between
hMS-1 and the respective mutant RBD proteins was then measured
by ELISA as described (Gao et al., 2013; Lu et al., 2013). hMS-1 was
not capable of recognizing the RBD of the R511A mutant and
reduced its binding to RBDs with mutations at D510A and W553A,
respectively (Fig. 3A). In comparison, the remaining mutations on
the RBD did not affect the binding between hMS-1 and RBD with
the exception of L506A, which exhibited a slight loss of binding
activity. A pseudovirus neutralization assay further revealed thatFig. 2. hMS-1 blocks the binding between MERS-CoV RBD and the hDPP4 receptor. The bloc
ﬂow cytometric analysis. (A) Blockage of Fc-fused MERS-CoV RBD protein binding to Huh-7
RBD to Huh-7 cells in the absence of antibody; blue line, irrelevant Trastuzumab mAb cont
cytometric analysis shows that hMS-1 inhibited the binding between the Fc-fused RBD prot
percentages of inhibition ± SEM (n ¼ 3). (For interpretation of the references to colour inpseudotyped MERS-CoV expressing the spike protein containing
R511A, D510A, orW553Amutants completely abolished (R511A), or
reduced (D510A or W553A) the inhibitory effect of hMS-1 on
pseudovirus infection. In contrast, L506A did not change the ability
of hMS-1 to inhibit MERS pseudovirus infection (Fig. 3B). These
results indicate that the R511 residue of RBD is a crucial neutralizing
epitope recognized by hMS-1.
Alignment of 278 full-length spike protein sequences deposited
in the NCBI MERS-CoV database illustrated that the RBD epitope
recognized by hMS-1 is highly conserved among MERS-CoV
emergent isolates (Supplementary Fig. 1). In particular, the R511
residue was not naturally mutated during MERS-CoV evolution,
indicating the ability of hMS-1 to cross-neutralize MERS-CoV
emergent strains. To further understand whether the natural RBD
mutations of the evolved strains of MERS-CoV isolated from the
2012 to 2015 outbreaks affected the hMS-1 neutralizing activity, we
constructed a series of pseudoviruses expressing MERS-CoV spike
proteins with these mutated RBD residues. hMS-1 exhibited potent
neutralizing activities toward all MERS mutant pseudoviruses
tested, with ND50 values ranging from 0.009 to 0.091 mg/ml
(Table 2). These results suggest that hMS-1 exhibits the ability to
cross-neutralize emergent MERS-CoV isolates.3.4. Single-dose treatment of humanized mAb hMS-1 provides full
protection from lethal MERS-CoV infection in the hDPP4-Tg mouse
model
Because wild-type mice are not permissive to MERS-CoV
infection (Coleman et al., 2014), the passive immunotherapeutic
effect of hMS-1 was evaluated in the hDPP4-Tg mouse model inking effect of hMS-1 on the cell-binding activity of MERS-CoV RBD was determined by
cells by 20 mg/ml hMS-1. Black line, Huh-7 cell control; purple line, binding of Fc-fused
rol; red line, MERS-CoV RBD binding of Huh-7 cells in the presence of hMS-1. (B) Flow
ein and Huh-7 cells in a dose-dependent manner. The data are presented as the mean
this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Mapping of epitopes recognized by hMS-1 in MERS-CoV RBD. (A) Binding of hMS-1 to RBD mutant proteins as detected by ELISA. (B) Neutralizing activity of hMS-1 to
pseudovirus mutants in a pseudovirus-based neutralization assay. Data are presented as the means ± SEM (n ¼ 2). Protein and pseudovirus without mutations served as the wild
type (WT) controls.
Table 2
Cross-neutralizing activities of hMS-1 against pseudotyped MERS-CoV mutantsa.
Accession No. Representative isolates Country Isolate date RBD mutationsb ND50 (mg/ml)
AFS88936 EMC2012 Saudi Arabia 2012/6/13 d c 0.089
AFY13307 England 1 United Kingdom 2012/9/11 L506F 0.049
AHI48725 Asir_1c_2013 Saudi Arabia 2013/7/2 A434V 0.044
AHI48528 Riyadh_9_2013 Saudi Arabia 2013/7/17 A431P; A482V 0.087
AHC74088 Qatar3 Qatar 2013/10/13 S460F 0.023
AID55087 Jeddah_C9313/KSA/2014 Saudi Arabia 2014 Q522H 0.044
AID55090 Riyadh_2014KSA_059/KSA/2014 Saudi Arabia 2014 T424I 0.009
AKL59401 KOR/KNIH/002_05_2015 South Korea 2015/5/20 V530L 0.091
ALJ54520 Hu/Hufuf-KSA-12597/2015 Saudi Arabia 2015/6/13 V534A 0.039
a A pseudovirus-based neutralization assay was performed to evaluate the cross-neutralization of hMS-1 against different MERS-CoV isolates. Pseudotyped MERS-CoV
mutants were generated containing corresponding RBD mutations in the spike protein of MERS-CoV representative isolates from years 2012e2015.
b RBD residues mutated in the spike proteins of the respective pseudotyped MERS-CoV mutants are indicated.
c The pseudotyped MERS-CoV expressing the spike protein of the EMC2012 strain was considered to be the prototype pseudovirus. ND50 was determined by using a
pseudotyped MERS-CoV-based neutralization assay.
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following lethal infection of MERS-CoV (104.6 TCID50 EMC2012),
hDPP4-Tg mice were intravenously injected with a single-dose
(2 mg/kg) of hMS-1 or the trastuzumab mAb control and viral ti-
ters, histopathological changes, body weight changes, and survival
rates were calculated. Viral titers weremeasured frommouse lungs
at three days following viral infection; these demonstrated that
mice receiving hMS-1 treatment exhibited signiﬁcantly lower viral
titers than those receiving the trastuzumab mAb control (p < 0.01)
(Fig. 4A), suggesting that hMS-1 can inhibit MERS-CoV infection
in vivo. Further examination of associated histopathological
changes illustrated that hMS-1 treatment signiﬁcantly alleviated
the lung injury induced by MERS-CoV infection (p < 0.01) (Fig. 4B).
The hMS-1-treated hDPP4-Tg mice under lethal MERS-CoV infec-
tion exhibited fewer histopathological changes (Fig. 4CeF), and
were accompanied by only a small degree of inﬂammatory cell
inﬁltration in the lung interstitial tissues (Fig. 4E, F). In contrast,
severe lung damage was observed in the control mice (Fig. 4GeJ),
which developed marked interstitial pneumonia with focal
exudation (Fig. 4H), macrophage inﬁltration (Fig. 4I), hemorrhage(Fig. 4J), and alveolar septal thickening (Fig. 4H, J). In addition, hMS-
1-treated mice exhibited only slight decreases of body weight by
day 11 followed by subsequent recovery, whereas control mice
demonstrated dramatic body weight loss (Fig. 5A). Notably, all
hMS-1-treated mice survived lethal MERS-CoV infection whereas
all control group animals died by day 10 post-infection (p < 0.01)
(Fig. 5B). These results conﬁrmed that single-dose hMS-1 mAb
treatment was able to completely protect hDPP4-Tg mice from le-
thal MERS-CoV infection.
4. Discussion
MERS-CoV infects humans with high associated mortality,
posing a large threat to public health and reinforcing the urgency to
develop effective vaccines and therapeutics. A number of thera-
peutic mAbs have been applied clinically to prevent and treat viral
infections (Murray et al., 2014; Qiu et al., 2014), suggesting that
neutralizing mAbs might represent a promising approach to com-
bat MERS-CoV infection as well. The MERS-CoV RBD can elicit
strong neutralizing antibody response and contains a critical
Fig. 4. Therapeutic treatment with hMS-1 limits lung viral replication and alleviates lung injury induced by MERS-CoV infection. (A) Viral titers detected in the mouse lung at day 3
post-infection (n ¼ 5). The data are expressed as the means ± SEM. **p < 0.01. The dotted line indicates the limit of detection. (B) Semiquantitative histopathological analysis of
H&E-stained lung sections from mice sacriﬁced at day 3 post-infection (n ¼ 5). The data are expressed as the means ± SEM. **p < 0.01. (CeJ) Representative H&E-stained lung
sections of hMS-1- and Trastuzumab-treated hDPP4 Tg mice, including locations on the trachea (D, H), vessel (E, I), and interstitial area (F, J) (scale bars, 100 mm for C, G; 50 mm for
DeF, HeJ).
Fig. 5. Single-dose treatment of hMS-1 fully protects hDPP4 transgenic mice from lethal MERS-CoV infection. The hDPP4 transgenic mice were administered a single-dose of hMS-1
or the irrelevant Trastuzumab 24 h after lethal infection of MERS-CoV and then monitored for 23 days. (A) Body weight changes of hMS-1- and Trastuzumab-treated mice. Results
are expressed as the means ± SEM (n ¼ 6). (B) Survival rate (%) of hMS-1- and Trastuzumab-treated mice (n ¼ 6). **p < 0.01.
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representing an ideal target for neutralizing mAb development.
Notably, almost all reported MERS-CoV neutralizing mAbs
including murine, human, and humanized mAbs, target the RBD
(Corti et al., 2015; Du et al., 2014; Jiang et al., 2014; Li et al., 2015;
Pascal et al., 2015; Tang et al., 2014; Ying et al., 2014; Yu et al.,
2015). We previously developed an RBD-targeting murine
neutralizing mAb, Mersmab1, and demonstrated its ability to
neutralize MERS-CoV infection (Du et al., 2014). Here, we further
humanized this mAb and evaluated its binding afﬁnity to RBD,
inhibitory ability against RBD-hDPP4 binding, and neutralizing and
cross-neutralizing activity against divergent MERS-CoV strains
isolated from the 2012e2015 outbreaks. The therapeutic potential
of the humanized hMS-1 mAb was also investigated in hDPP4-Tg
mice.
Our data clearly showed that humanized hMS-1 mAb main-
tained strong reactivity to the RBD, signiﬁcantly blocking RBD/
hDPP4 receptor binding and potently neutralizing MERS-CoV
infection. As it has been demonstrated that MERS-CoV underwent
evolution during the 2012e2015 outbreaks (Cotten et al., 2013;
Sabir et al., 2016), we evaluated the hMS-1 cross-neutralizing ac-
tivity against these MERS-CoV emergent strains. hMS-1 recognized
three key residues (neutralizing epitopes) of MERS-CoV RBD all of
which were highly conserved during MERS-CoV evolution, leading
to the hypothesis that hMS-1 might be effective in combatting the
infections of differentMERS-CoV emerging isolates. Notably, hMS-1
could potently neutralize a series of pseudoviruses expressing the
spike proteins of MERS-CoVs isolated from outbreaks in different
regions including Saudi Arabia and South Korea over the
2012e2015 period, demonstrating its cross-neutralizing activity
against MERS-CoV spread and evolution.
Several neutralizing mAbs including LCA60, REGN3051,
REGN3048, 4C2h, and m336 have been tested in vivo for their
protective efﬁcacy using non-lethal MERS-CoV challenge mouse or
rabbit models (Corti et al., 2015; Li et al., 2015; Pascal et al., 2015;
Houser et al., 2016). In this study, we evaluated the protective ef-
ﬁcacy of hMS-1 in a lethal hDPP4-Tg mouse model, wherein we
demonstrated that a single-dose (2 mg/kg) of hMS-1 completely
protected hDPP4-Tg mice from a lethal challenge from MERS-CoV.
This study therefore suggests that hMS-1 might be further devel-
oped as a potent passive therapeutic agent to treat patients infected
with MERS-CoV.
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Appendix A
MERS-CoV isolates for multiple sequence alignment.
A total of 278 full-length of spike proteins of MERS-CoV isolates
were collected for multiple sequence alignment. GenBank Acces-
sion numbers of collected sequences are listed as follows.
AIZ74439; AHL18090; ALS20350; AGH58717; AHY21469;
AKM76239; AHY22565; ALJ54461; ALR69641; AHX00711;
AHX00721; AHX00731; AHY22555; ALJ54472; ALA49649;
AKN24812; ALB08311; ALB08322; ALJ54451; ALJ54455; ALJ54490;
ALJ54456; AJG44069; AIY60578; AJG44058; AJG44091;
AKM76229; AJG44080; ALA49803; ALA49814; ALJ54474;
ALA49671; AHI48528; AKL59401; AKN24803; ALA49660;
ALJ54471; ALJ54517; ALJ54495; AJG44102; AJG44113; ALJ54452;
ALW82753; AIZ74433; AHB33326; AIZ74417; AIZ74450; AJG44124;ALT66870; ALT66880; AIY60518; AIY60538; AIY60548; AIY60558;
AIY60568; AIY60588; AIY60528; AHI48550; AGN52936;
AFS88936; AGV08390; AFY13307; AGG22542; AHE78097;
AHE78108; AHI48594; AHI48605; AHN10812; AHI48583;
ALA49374; ALA49693; ALA49704; AHZ58501; AID55073;
AKN24749; AKN24758; AKN24767; AKN24776; AKN24785;
AKN24794; AKN24821; AKN24830; ALA49396; ALA49407;
ALA49418; ALA49429; ALA49836; ALA49902; ALA49946;
ALA50067; ALA49385; ALA49550; ALA49561; ALA49572;
ALA49616; ALA49627; ALA49638; ALA49682; ALA50034;
ALA50045; ALJ54475; ALJ54477; ALJ54478; ALJ54479; ALJ54480;
ALJ54493; ALJ54450; ALJ54481; ALJ54484; ALJ54486; ALJ54496;
ALW82691; ALJ54518; ALA49341; ALJ54446; ALJ54468;
AGN70929; AGN70951; AGN70962; AGN70973; AGV08444;
AGV08480; AGV08535; AGV08546; AGV08558; AGV08573;
AHI48517; AGV08492; ALA49473; ALA49495; ALA49462;
ALA49484; ALA49506; ALA49517; ALA49528; ALA49539;
ALA49583; ALA49594; ALA49605; ALA49715; ALA49726;
ALA49737; ALA49748; ALA49759; ALA49770; ALA49781;
ALA49792; ALJ54502; AID55066; AID55067; AID55068; AID55069;
AID55070; AID55071; AID55072; AHZ64057; AIZ48760; ALJ54501;
ALD51904; AGV08467; AHX71946; AHY22545; AJD81440;
ALA49363; ALA49451; ALJ54453; ALJ54467; ALJ54491; ALJ54500;
ALJ54508; ALJ54512; ALJ54516; ALJ54521; ALW82742; AGV08379;
AGV08408; AGV08584; ALJ54520; AHC74088; AHC74098;
ALA49352; ALJ54463; ALA49957; ALA49968; ALB08246;
ALB08257; ALJ54458; ALJ54483; ALJ54488; ALJ54497; AGV08455;
AHI48539; AHI48561; AKI29255; AKI29265; AKI29275; AKI29284;
ALJ54441; ALJ54442; ALJ54443; ALB08267; ALB08278; ALB08289;
ALB08300; ALJ54448; ALJ54465; ALJ54466; AHI48572; AHY22525;
AHY22535; AID50418; AJD81451; AKJ80137; AKK52582;
AKK52592; AKK52602; AKK52612; AKQ21055; AKQ21064;
AKQ21073; ALA49440; ALA49825; ALA49847; ALA49858;
ALA49869; ALA49880; ALA49891; ALA49913; ALA49924;
ALA49935; ALA49979; ALA49990; ALA50001; ALA50012;
ALA50023; ALA50056; ALJ54444; ALJ54445; ALJ54447; ALJ54449;
ALJ54454; ALJ54457; ALJ54459; ALJ54460; ALJ54462; ALJ54464;
ALJ54469; ALJ54470; ALJ54473; ALJ54476; ALJ54482; ALJ54485;
ALJ54487; ALJ54489; ALJ54492; ALJ54494; ALJ54498; ALJ54499;
ALJ54503; ALJ54504; ALJ54505; ALJ54506; ALJ54507; ALJ54509;
ALJ54510; ALJ54511; ALJ54513; ALJ54514; ALJ54515; ALJ54519;
ALW82636; ALW82647; ALW82658; ALW82669; ALW82680;
ALW82709; ALW82720; ALW82731.
Appendix. BSupplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.antiviral.2016.06.003.
References
Bonavia, A., Zelus, B.D., Wentworth, D.E., Talbot, P.J., Holmes, K.V., 2003. Identiﬁ-
cation of a receptor-binding domain of the spike glycoprotein of human coro-
navirus HCoV-229E. J. Virol. 77, 2530e2538.
Boulianne, G.L., Hozumi, N., Shulman, M.J., 1984. Production of functional chimaeric
mouse/human antibody. Nature 312, 643e646.
Brister, J.R., Bao, Y., Zhdanov, S.A., Ostapchuck, Y., Chetvernin, V., Kiryutin, B.,
Zaslavsky, L., Kimelman, M., Tatusova, T.A., 2014. Virus variation resourcedre-
cent updates and future directions. Nucleic Acids Res. 42, D660eD665.
Coleman, C.M., Matthews, K.L., Goicochea, L., Frieman, M.B., 2014. Wild-type and
innate immune-deﬁcient mice are not susceptible to the Middle East respira-
tory syndrome coronavirus. J. General Virol. 95, 408e412.
Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., Fernandez-
Rodriguez, B., Foglierini, M., Agatic, G., Vanzetta, F., Gopal, R., Langrish, C.J.,
Barrett, N.A., Sallusto, F., Baric, R.S., Varani, L., Zambon, M., Perlman, S.,
Lanzavecchia, A., 2015. Prophylactic and postexposure efﬁcacy of a potent hu-
man monoclonal antibody against MERS coronavirus. Proc. Natl. Acad. Sci. U. S.
A. 112, 10473e10478.
Cotten, M., Watson, S.J., Kellam, P., Al-Rabeeah, A.A., Makhdoom, H.Q., Assiri, A., Al-
H. Qiu et al. / Antiviral Research 132 (2016) 141e148148Tawﬁq, J.A., Alhakeem, R.F., Madani, H., AlRabiah, F.A., Hajjar, S.A., Al-
nassir, W.N., Albarrak, A., Flemban, H., Balkhy, H.H., Alsubaie, S., Palser, A.L.,
Gall, A., Bashford-Rogers, R., Rambaut, A., Zumla, A.I., Memish, Z.A., 2013.
Transmission and evolution of the Middle East respiratory syndrome corona-
virus in Saudi Arabia: a descriptive genomic study. Lancet 382, 1993e2002.
de Groot, R.J., Baker, S.C., Baric, R.S., Brown, C.S., Drosten, C., Enjuanes, L.,
Fouchier, R.A., Galiano, M., Gorbalenya, A.E., Memish, Z.A., Perlman, S.,
Poon, L.L., Snijder, E.J., Stephens, G.M., Woo, P.C., Zaki, A.M., Zambon, M.,
Ziebuhr, J., 2013. Middle East respiratory syndrome coronavirus (MERS-CoV):
announcement of the Coronavirus Study Group. J. Virol. 87, 7790e7792.
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., Jiang, S., 2009. The spike protein of SARS-
CoVd a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7,
226e236.
Du, L., Jin, L., Zhao, G., Sun, S., Li, J., Yu, H., Li, Y., Zheng, B.-J., Liddington, R.C., Zhou, Y.,
Jiang, S., 2013a. Identiﬁcation and structural characterization of a broadly
neutralizing antibody targeting a novel conserved epitope on the inﬂuenza
virus H5N1 hemagglutinin. J. Virol. 87, 2215e2225.
Du, L., Kou, Z., Ma, C., Tao, X., Wang, L., Zhao, G., Chen, Y., Yu, F., Tseng, C.-T.K.,
Zhou, Y., Jiang, S., 2013b. A truncated receptor-binding domain of MERS-CoV
spike protein potently inhibits MERS-CoV infection and induces strong
neutralizing antibody responses: implication for developing therapeutics and
vaccines. PLoS ONE 8, e81587.
Du, L., Zhao, G., Yang, Y., Qiu, H., Wang, L., Kou, Z., Tao, X., Yu, H., Sun, S., Tseng, C.T.,
Jiang, S., Li, F., Zhou, Y., 2014. A conformation-dependent neutralizing mono-
clonal antibody speciﬁcally targeting receptor-binding domain in Middle East
respiratory syndrome coronavirus spike protein. J. Virol. 88, 7045e7053.
Edgar, R.C., 2004. MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res. 32, 1792e1797.
Gao, J., Lu, G., Qi, J., Li, Y., Wu, Y., Deng, Y., Geng, H., Li, H., Wang, Q., Xiao, H., Tan, W.,
Yan, J., Gao, G.F., 2013. Structure of the fusion core and inhibition of fusion by a
heptad repeat peptide derived from the S protein of Middle East respiratory
syndrome coronavirus. J. Virol. 87, 13134e13140.
Houser, K.V., Gretebeck, L., Ying, T., Wang, Y., Vogel, L., Lamirande, E.W., Bock, K.W.,
Moore, I.N., Dimitrov, D.S., Subbarao, K., 2016. Prophylaxis with a Middle East
respiratory syndrome coronavirus (MERS-CoV)-speciﬁc human monoclonal
antibody protects rabbits from MERS-CoV infection. J. Infect. Dis. 213,
1557e1561.
Jiang, L., Wang, N., Zuo, T., Shi, X., Poon, K.M., Wu, Y., Gao, F., Li, D., Wang, R., Guo, J.,
Fu, L., Yuen, K.Y., Zheng, B.J., Wang, X., Zhang, L., 2014. Potent neutralization of
MERS-CoV by human neutralizing monoclonal antibodies to the viral spike
glycoprotein. Sci. Transl. Med. 6, 234ra259.
Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., Wang, Q., Lu, X., Wu, Y., Liu, W., Zhang, B.,
Yuen, K.Y., Perlman, S., Gao, G.F., Yan, J., 2015. A humanized neutralizing anti-
body against MERS-CoV targeting the receptor-binding domain of the spike
protein. Cell Res. 25, 1237e1249.
Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J.,
Zhang, B., Shi, Y., Yan, J., Gao, G.F., 2013. Molecular basis of binding between
novel human coronavirus MERS-CoV and its receptor CD26. Nature 500,
227e231.
Ma, C., Wang, L., Tao, X., Zhang, N., Yang, Y., Tseng, C.T., Li, F., Zhou, Y., Jiang, S., Du, L.,
2014. Searching for an ideal vaccine candidate among different MERS corona-
virus receptor-binding fragmentsethe importance of immunofocusing in sub-
unit vaccine design. Vaccine 32, 6170e6176.
Murray, J., Saxena, S., Sharland, M., 2014. Preventing severe respiratory syncytial
virus disease: passive, active immunisation and new antivirals. Archives Dis.
Child. 99, 469e473.
Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C.,
Strein, J., Berrebi, A., Sisk, J.M., Matthews, K.L., Babb, R., Chen, G., Lai, K.-M.V.,
Huang, T.T., Olson, W., Yancopoulos, G.D., Stahl, N., Frieman, M.B.,
Kyratsous, C.A., 2015. Pre- and postexposure efﬁcacy of fully human antibodies
against Spike protein in a novel humanized mouse model of MERS-CoV infec-
tion. Proc. Natl. Acad. Sci. U. S. A. 112, 8738e8743.
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-
Bovendo, H., Wei, H., Aviles, J., Hiatt, E., Johnson, A., Morton, J., Swope, K.,
Bohorov, O., Bohorova, N., Goodman, C., Kim, D., Pauly, M.H., Velasco, J.,
Pettitt, J., Olinger, G.G., Whaley, K., Xu, B., Strong, J.E., Zeitlin, L., Kobinger, G.P.,
2014. Reversion of advanced Ebola virus disease in nonhuman primates with
ZMapp(™). Nature 514, 47e53.Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Muller, M.A., Dijkman, R., Muth, D.,
Demmers, J.A., Zaki, A., Fouchier, R.A., Thiel, V., Drosten, C., Rottier, P.J.,
Osterhaus, A.D., Bosch, B.J., Haagmans, B.L., 2013. Dipeptidyl peptidase 4 is a
functional receptor for the emerging human coronavirus-EMC. Nature 495,
251e254.
Reed, L., Muench, H., 1938. A simple method of estimating ﬁfty per cent endpoints.
Am. J. Hyg. 493e497.
Sabir, J.S.M., Lam, T.T.Y., Ahmed, M.M.M., Li, L., Shen, Y.E.M., Abo-Aba, S.,
Qureshi, M.I., Abu-Zeid, M., Zhang, Y., Khiyami, M.A., Alharbi, N.S., Hajrah, N.H.,
Sabir, M.J., Mutwakil, M.H.Z., Kabli, S.A., Alsulaimany, F.A.S., Obaid, A.Y., Zhou, B.,
Smith, D.K., Holmes, E.C., Zhu, H., Guan, Y., 2016. Co-circulation of three camel
coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science
351, 81e84.
Skowronski, D.M., Astell, C., Brunham, R.C., Low, D.E., Petric, M., Roper, R.L.,
Talbot, P.J., Tam, T., Babiuk, L., 2004. Severe acute respiratory syndrome (SARS):
a year in review. Annu. Rev. Med. 56, 357e381.
Sun, S., Zhao, G., Liu, C., Wu, X., Guo, Y., Yu, H., Song, H., Du, L., Jiang, S., Guo, R.,
Tomlinson, S., Zhou, Y., 2013. Inhibition of complement activation alleviates
acute lung injury induced by highly pathogenic avian inﬂuenza H5N1 virus
infection. Am. J. Respir. Cell Mol. Biol. 49, 221e230.
Tang, X.C., Agnihothram, S.S., Jiao, Y., Stanhope, J., Graham, R.L., Peterson, E.C.,
Avnir, Y., Tallarico, A.S., Sheehan, J., Zhu, Q., Baric, R.S., Marasco, W.A., 2014.
Identiﬁcation of human neutralizing antibodies against MERS-CoV and their
role in virus adaptive evolution. Proc. Natl. Acad. Sci. U. S. A. 111, E2018eE2026.
Tao, X., Hill, T.E., Morimoto, C., Peters, C.J., Ksiazek, T.G., Tseng, C.-T.K., 2013. Bilateral
entry and release of Middle East respiratory syndrome coronavirus induces
profound apoptosis of human bronchial epithelial cells. J. Virol. 87, 9953e9958.
Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., Guo, D., Fu, L., Cui, Y., Liu, X.,
Arledge, K.C., Chen, Y.H., Zhang, L., Wang, X., 2013. Structure of MERS-CoV spike
receptor-binding domain complexed with human receptor DPP4. Cell Res. 23,
986e993.
Xu, Y., Lou, Z., Liu, Y., Pang, H., Tien, P., Gao, G.F., Rao, Z., 2004. Crystal structure of
severe Acute respiratory syndrome coronavirus spike protein fusion core. J. Biol.
Chem. 279, 49414e49419.
Ying, T., Du, L., Ju, T.W., Prabakaran, P., Lau, C.C., Lu, L., Liu, Q., Wang, L., Feng, Y.,
Wang, Y., Zheng, B.J., Yuen, K.Y., Jiang, S., Dimitrov, D.S., 2014. Exceptionally
potent neutralization of Middle East respiratory syndrome coronavirus by hu-
man monoclonal antibodies. J. Virol. 88, 7796e7805.
Yu, X., Zhang, S., Jiang, L., Cui, Y., Li, D., Wang, D., Wang, N., Fu, L., Shi, X., Li, Z.,
Zhang, L., Wang, X., 2015. Structural basis for the neutralization of MERS-CoV by
a human monoclonal antibody MERS-27. Sci. Rep. 5, 13133.
Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., 2012.
Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
N. Engl. J. Med. 367, 1814e1820.
Zhang, N., Channappanavar, R., Ma, C., Wang, L., Tang, J., Garron, T., Tao, X.,
Tasneem, S., Lu, L., Tseng, C.T., Zhou, Y., Perlman, S., Jiang, S., Du, L., 2016.
Identiﬁcation of an ideal adjuvant for receptor-binding domain-based subunit
vaccines against Middle East respiratory syndrome coronavirus. Cell Mol.
Immunol. 13, 180e190.
Zhao, G., Du, L., Ma, C., Li, Y., Li, L., Poon, V.K.M., Wang, L., Yu, F., Zheng, B.-J., Jiang, S.,
Zhou, Y., 2013. A safe and convenient pseudovirus-based inhibition assay to
detect neutralizing antibodies and screen for viral entry inhibitors against the
novel human coronavirus MERS-CoV. Virol. J. 10, 266.
Zhao, G., Jiang, Y., Qiu, H., Gao, T., Zeng, Y., Guo, Y., Yu, H., Li, J., Kou, Z., Du, L., Tan, W.,
Jiang, S., Sun, S., Zhou, Y., 2015. Multi-organ damage in human dipeptidyl
peptidase 4 transgenic mice infected with Middle East respiratory syndrome-
coronavirus. PLoS One 10, e0145561.
Zhong, N.S., Zheng, B.J., Li, Y.M., Poon, L.L.M., Xie, Z.H., Chan, K.H., Li, P.H., Tan, S.Y.,
Chang, Q., Xie, J.P., Liu, X.Q., Xu, J., Li, D.X., Yuen, K.Y., Peiris, J.S.M., Guan, Y.,
2003. Epidemiology and cause of severe acute respiratory syndrome (SARS) in
Guangdong, People’s Republic of China, in February, 2003. Lancet 362,
1353e1358.
Zhu, X., Guo, Y.-H., Jiang, T., Wang, Y.-D., Chan, K.-H., Li, X.-F., Yu, W., McBride, R.,
Paulson, J.C., Yuen, K.-Y., Qin, C.-F., Che, X.-Y., Wilson, I.A., 2013. A unique and
conserved neutralization epitope in H5N1 inﬂuenza viruses identiﬁed by an
antibody against the A/Goose/Guangdong/1/96 hemagglutinin. J. Virol. 87,
12619e12635.
